Karuna Therapeutics, Inc. Common Stock
KRTX
KRTX was delisted on the 15th of March, 2024.
195 hedge funds and large institutions have $3.77B invested in Karuna Therapeutics, Inc. Common Stock in 2022 Q2 according to their latest regulatory filings, with 37 funds opening new positions, 76 increasing their positions, 62 reducing their positions, and 16 closing their positions.
131% more first-time investments, than exits
New positions opened: 37 | Existing positions closed: 16
23% more repeat investments, than reductions
Existing positions increased: 76 | Existing positions reduced: 62
16% more call options, than puts
Call options by funds: $85.8M | Put options by funds: $74M
10% more funds holding
Funds holding: 177 → 195 (+18)
1% more capital invested
Capital invested by funds: $3.73B → $3.77B (+$33.7M)
0% more funds holding in top 10
Funds holding in top 10: 8 → 8 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital International Investors
Los Angeles,
California
|
+$107M |
| 2 |
BlackRock
New York
|
+$29.9M |
| 3 |
APM
Avidity Partners Management
Dallas,
Texas
|
+$23.5M |
| 4 |
State Street
Boston,
Massachusetts
|
+$18.6M |
| 5 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$17.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jennison Associates
New York
|
-$34.7M |
| 2 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$28.7M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
-$24.3M |
| 4 |
LGM
Logos Global Management
San Francisco,
California
|
-$21.8M |
| 5 |
EA
Emerald Advisers
Leola,
Pennsylvania
|
-$15.4M |
KRTX Hedge Fund Activity: Q2 2022 in Review
195 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Karuna Therapeutics, Inc. Common Stock (KRTX) for Q2 2022, worth a combined $3.77B — up 0.9% from $3.73B a quarter earlier.
Buyers outnumbered sellers: 37 funds opened new KRTX positions and 16 closed out — a net gain of 21 holders — while 76 added to existing stakes and 62 trimmed.
The largest buyer was Capital International Investors, adding an estimated $107M. The largest seller was Jennison Associates, exiting entirely with an estimated $34.7M sold.
- 195 institutional investors held Karuna Therapeutics, Inc. Common Stock (KRTX) as of Q2 2022, up from 177 in Q1 2022.
- Funds reported $3.77B of Karuna Therapeutics, Inc. Common Stock stock for Q2 2022, up 0.9% quarter-over-quarter.
- 37 funds opened new Karuna Therapeutics, Inc. Common Stock positions in Q2 2022 and 16 closed out, a net change of +21 holders.
- The largest Karuna Therapeutics, Inc. Common Stock buyer in Q2 2022 was Capital International Investors, an estimated $107M added.
- The largest Karuna Therapeutics, Inc. Common Stock seller in Q2 2022 was Jennison Associates, an estimated $34.7M sold.
Based on aggregated 13F filings for Q2 2022.